MedTrace Logo

Treatment of Aggressive Localized Lymphoma

NCT00841945 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2017-02-23

No results posted yet for this study

Summary

Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma , age 18 to 75 years.

Conditions

  • B Cell Lymphoma

Interventions

DRUG

rituximab

RITUXIMAB 375 MG/M² IV DAY 1 or each course

DRUG

doxorubicin

doxorubicin 50 mg / m² iv day 1 of each course

DRUG

vincristine

VINCRISTINE 1?4 MG/M² IV ON DAY 1

DRUG

prednisone

Prednisone 40 mg/m² DAy 1 to day 5

PROCEDURE

radiotherapy

radiotherapy : total dose = 40 GY (5 fractions by week)

Sponsors & Collaborators

  • French Innovative Leukemia Organisation

    lead OTHER

Principal Investigators

  • Thierry LAMY, MD PhD · French Innovative Leukemia Organisation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2016-01-31
Completion
2017-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841945 on ClinicalTrials.gov